Cerebrolysin vs Cortexin
How Cerebrolysin and Cortexin compare — what each is, how strong the human evidence is for each, doses reported in research, the key risks, and 2026 US legal status. No universal winner.
Cerebrolysin and Cortexin come up together when people are weighing similar options. Here's the honest side-by-side: what each is, how strong the human evidence is for each, the doses reported in research, the risks, and where each stands with the FDA as of 2026. There's no universal winner — scroll to the by-goal picks for which one fits which goal.
Cerebrolysin vs Cortexin, point by point
Every dimension side by side — the honest differences, not a scoreboard.
| Dimension | Cerebrolysin | Cortexin |
|---|---|---|
| What it is | Peptide preparation — a standardized mixture of low-molecular-weight neuropeptides and free amino acids enzymatically processed from purified porcine (pig) brain proteins, not a single defined molecule. | Animal-derived nootropic preparation: a mixture of low-molecular-weight polypeptides extracted from cattle cerebral cortex, not one defined peptide |
| Class / category | Nootropic / mental-health | Nootropic / mental-health |
| Evidence tier | Human RCT · Mixed | Animal-only · Unclear · none in humans |
| Studied / approved for | Ischaemic stroke recovery; Vascular dementia and cognitive decline; Traumatic brain injury recovery; Alzheimer's disease | Cognitive impairment associated with cerebrovascular disease; Recovery after ischemic stroke; Developmental delay after early brain injury; Healthy-person cognitive enhancement |
| US regulatory status (2026) | research use only (as of Jul 2026) | research use only (as of Jul 2026) |
| Doses reported in research | No established study doses | No established study doses |
| Registered trials (ClinicalTrials.gov) | 42 | No data |
| Banned in sport (WADA) | Unknown | Unknown |
| Key risks | Cerebrolysin is generally well tolerated in trials, with the common complaints being injection-site reactions, dizziness, headache and a warm or flushed feeling — usually mild and often tied to fast infusion. Serious reactions are rare but reported, and long-term safety data for the off-label "nootropic" use in healthy people essentially doesn't exist. | Cortexin lacks a strong, independently replicated human safety record for healthy nootropic use. Injection adds risks involving sterility, product identity, local injury, and hypersensitivity. Because the active material comes from cattle brain, transmissible-spongiform-encephalopathy controls and source traceability matter; public evidence does not quantify Cortexin's residual prion risk. |
- Evidence tier: A tier reflects how human the evidence is, not a promise the compound works.
Which one fits which goal?
There's no universal winner here — the honest answer depends on what you're after. These picks are framed by goal, and each says why.
If you want the option with more human evidence behind it
Leans toward Cerebrolysin
Cerebrolysin's evidence sits at human rct, a more human tier than Cortexin's animal-only. That reflects how the data was gathered, not a guarantee it works.
References
- 1.Cerebrolysin — indexed research (PubMed, National Library of Medicine)
- 2.Cerebrolysin — registered clinical studies (ClinicalTrials.gov)
- 3.Cochrane systematic reviews of cerebrolysin (acute stroke, vascular dementia)
- 4.FDA — drug approvals and status information
- 5.Kurkin et al., 2025 — Neurotropic Effects of Cortexin (PMID 40299434)
- 6.Al-Sulaimani et al. — Systematic review of animal-derived nootropics